Pharmaxis wins approval to sell Aridol in Germany

Aridol is indicated for measuring airway hyperresponsiveness and has been approved in 14 European countries under the mutual recognition procedure (MRP). The necessary national approvals that follow the MRP have now been received for Denmark, Germany, Ireland, The Netherlands, Portugal, Sweden, and the UK.

Aridol, an airways inflammation test, is a dry powder administered to patients’ lungs via a small hand-held inhaler. Doctors can use the results of this test to identify airway hyperresponsiveness – a hallmark of asthma. Medications can be adjusted according to the severity of the disease.

Alan Robertson, CEO of Pharmaxis, said: “The Aridol test provides objective information on airway hyperresponsiveness and assists in the diagnosis and assessment of severity of asthma and how much medication should be used.”